















406The results of stent graft versus medication therapy
for chronic type B dissection
Xin Jia, MD,a Wei Guo, MD,a Tian-xiao Li, MD,b Sheng Guan, MD,c Rui-min Yang, MD,d
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Objective: This prospective multicenter comparative study examined early and midterm results of medication and stent-
graft therapies on chronic type B aortic dissection in China.
Methods: The study consisted of 303 consecutive patients with chronic type B aortic dissection from four centers in China
from January 2007 to December 2010 who were prospectively enrolled and treated by either optimal medical therapy
(OMT) or thoracic endovascular aorta repair (TEVAR). Of the patients, 219 were male and 84 were female (average age,
53.6 ± 20.3 years; range, 29-81 years). Baseline diameter of the thoracic aorta was 41.2 (19.1) mm (mean [standard
deviation]), and dissection extended beyond the celiac axis in 87.1% of cases.
Results: In total, there were 208 patients in the TEVAR group and 95 patients in the OMT group. Procedural success was
100%, and no deaths occurred during index hospitalization in the two groups. In the TEVAR group, two patients (0.9%)
suffered from retrograde type A dissection, and two (0.9%) suffered from paraplegia or paraparesis. For in-hospital
outcome, multivariate analysis revealed that age >75 years and American Society of Anesthesiologists class greater
than III were independent predictors of major early adverse events. Average follow-up time for hospital survivors was
28.5 ± 16.3 months (range, 1.0-58 months). In the OMT group, ﬁve patients died from rupture of an enlarged false
lumen, and six patients died suddenly of unknown reasons. Fourteen cases required crossover to TEVAR (n [ 12) or
surgical conversion (n[ 2). In the TEVAR group, nine patients required reintervention or surgical conversion, and one
died of postoperative multi-organ failure. One patient died of delayed retrograde type A dissection, and four died
suddenly of unknown reasons. The Kaplan-Meier analysis of survival probability at 2 and 4 years was 87.5% and 82.7%
with TEVAR, respectively, and 77.5% and 69.1% with OMT, respectively (P [ .0678, log-rank test). The estimated
cumulative freedom from aorta-related death at 2 and 4 years was 91.6% and 88.1% with TEVAR, respectively, and 82.8%
and 73.8% with OMT, respectively (P [ .0392, log-rank test). The thoracic aorta diameter decreased from 42.4 (23.1)
mm to 37.3 (12.8) mm in the TEVAR group and increased from 40.7 (18.6) mm to 48.1 (17.3) mm in the OMT group.
Conclusions: This was the ﬁrst prospective multicenter comparative study on the treatment of type B aortic dissection in
China. TEVAR had a signiﬁcantly lower aorta-related mortality compared with OMT but failed to improve overall
survival rate or lower the aorta-related adverse event rate. (J Vasc Surg 2013;57:406-14.)Aortic dissection is a catastrophic cardiovascular event
associated with highmorbidity andmortality rates. Different
from the management of patients with proximal dissection,
the management of patients with distal dissection (Stanford
type B) remains a matter of ongoing debate.1 Many institu-
tions favor a complication-speciﬁc approach to type B dissec-
tion, with optimal medical therapy (OMT) as the primary
therapeutic option and reserving thoracic endovascular aorta
repair (TEVAR) or open surgery for evolving complications
(eg, persistent pain, false-lumen expansion, visceral or
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OMT remains poor, mainly because of potential false-
lumen expansion. Reports have shown that mortality could
rise to 30% at 2 years and that long-term survival was
<50%.5-7
Relative few comparative data exist deﬁning the clinical
outcomes of TEVAR and OMT exclusively in the setting of
chronic type B dissection.8-12 However, Xiong et al13
found that patients with type B aortic dissection in China
were about 10 years younger than those in the Western
world. This ﬁnding might suggest a potentially different
pathology and underlying etiology of aortic dissection
among Chinese patients. Unfortunately, until now most
of the relevant studies on type B aortic dissection in China
were based on retrospective single-center experiences.14-16
This is the ﬁrst prospective multicenter comparative study
in China on the treatment of chronic type B dissection
with OMT and TEVAR.
METHODS
Patient characteristics. The study focused on data
from 303 consecutive patients with chronic type B aortic
dissection prospectively collected from January 2007 to
December 2010. Four Chinese referral centers (one in
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data from patients treated consecutively for type B aortic
dissection. Each responsible operator from the four centers
had completed at least 100 cases of TEVAR. The study
protocol was approved by the local ethical committee.
After an interim period of 14 days, during which early
complications were identiﬁed, all patients enrolled had
chronic uncomplicated type B aortic dissection. Written
informed consent was obtained from all patients. Treat-
ment during the index hospitalization or in follow-up was
not standardized but was at the discretion of the patient’s
treating physician and according to the patient’s request.
Inclusion criteria. The inclusion criteria were (1)
patients who were diagnosed as having uncomplicated
type B aorta dissection, (2) patients who were at least 20
years old but were younger than 80 years, and (3) patients
who were able to cooperate with the study procedure and
provided written informed consent.
Exclusion criteria. The exclusion criteria were (1)
patients who were younger than 20 years or were 80 years
or older, (2) patients who had a current medical condition
with a life expectancy <12 months, and (3) patients who
hadcomplicated typeBdissectionor aortadiameter>5.5 cm.
Medication therapy. During the acute phase, hyper-
tension was treated aggressively to lower systolic blood
pressure to <120 mm Hg, and b-adrenergic antagonists
were administered whenever tolerated. When the blood
pressure was stabilized, patients received oral antihyperten-
sive treatment. Long-term antihypertensive treatment was
initiated in all patients, including the TEVAR group, and
target blood pressure was <130/70 mm Hg.
Interventional procedures. Based on diagnostic
measurements obtained from multislice computed tomog-
raphy (CT) or magnetic resonance imaging (MRI), indi-
vidually selected Valiant (Medtronic Inc, Santa Rosa,
Calif), Zenith TX2 (Cook Inc, Bloomington, Ind), or
Hercules (Microport Medical Inc, Shanghai, China) stent
grafts were used to scaffold dissected thoracic aorta. The
procedure was performed with digital angiography. Over-
sizing by 10% to 20% was achieved according to the oper-
ator. The femoral artery usually could accommodate the
20F to 24F stent graft system, which was advanced over
a 260-cm stiff wire navigated in the true lumen and
deployed with systolic pressure lowered to #80 mm Hg
using sodium nitroprusside. Intentional coverage of the left
subclavian artery (LSA) was accepted to avoid endoleak. In
the presence of a lusorian artery, incomplete circle of Willis,
dominant left vertebral artery, or extensive coverage of
thoracic aorta, revascularization of the LSA with surgical
bypass or preservation of the LSA with “chimney tech-
nique” was performed at the discretion of the operator.
Follow-up. The follow-up protocol included contrast-
enhanced aortic imaging with CT or MRI before hospital
discharge, 6 and 12 months after hospital discharge, and
yearly thereafter. Because the majority of patients were
followed up outside the four centers, compliance with the
imaging surveillance protocol was variable. Follow-up
clinical status was obtained by contacting all survivingpatients or family members, and follow-up analysis was
performed based on clinical and imaging ﬁndings until the
last visit and included all adverse events. All clinical and
imaging data were extracted until December 2011.
Deﬁnitions. Chronic type B aortic dissection was
deﬁned as any nontraumatic dissection that involved the
descending aorta and appeared more than 14 days after
symptom onset. Intramural hematoma was not included
in this study. Procedural success was deﬁned as successful
deployment of the stent graft device. “Early” and “mid-
term” outcomes were deﬁned according to reporting
criteria as within 30 days of operation and from 30 days to
5 years after operation, respectively.
Clinical outcome and end points. Clinical outcome
and events were classiﬁed in accordance with reporting stan-
dards of the AdHoc Committee for Standardized Reporting
Practices in Vascular Surgery of the Society for Vascular
Surgery/American Association for Vascular Surgery.17 The
primary end point was all-cause death. Secondary end points
were aorta-relateddeath, a composite endpointofprogressive
aortic pathology (including crossover/conversion or addi-
tional endovascular or open surgery), and morphologic
changes of the aorta.
Statistical analysis. Data management and statistical
analyses were performed at the coordinating center of the
Chinese PLA General Hospital. The incidence of adverse
events is given as the number of patients experiencing the
event followed by the corresponding percentage. Contin-
uous data are reported as mean (standard deviation)
including range. For continuous variables, differences
between groups were evaluated using a two-sample t-test
or nonparametric Mann-Whitney U test depending on the
distribution of variables. Categorical variables were com-
pared by the Fisher exact test or c2 test. Time-to-event
curves were calculated by the Kaplan-Meier method and
compared by log-rank test on an intention-to-treat basis.
Stepwise logistic regression analysis was performed to
determine predictors of predeﬁned clinical end points.
Results are reported as odds ratio and 95% CI. Statistical
analyses were performed using the SPSS software package
(version 15.0; SPSS Inc, Chicago, Ill).
RESULTS
Baseline characteristics and procedural results. In
total, there were 208 patients in the TEVAR group and 95
patients in the OMT group (Fig 1). There was no signiﬁ-
cant difference in baseline demographic data between the
two groups (Table I). Themedian time interval fromonset of
dissection to TEVAR was 23 days (range, 16-57 days).
During follow-up, 12 cases required crossover fromOMT to
TEVAR, and ﬁve cases (three from TEVAR group and two
from OMT group) were converted to open surgery.
Procedural success was documented in 100% of cases.
The mean length of covered aorta was 147 mm (range,
54-280 mm), with only one stent graft used in 191 patients
(91.8%). In 15 cases, calciﬁcation or stenosis lesions at the
level of the femoral artery required retroperitoneal access to
the common iliac artery. In 36.5% of the cases (76/208),
Fig 1. Flowchart of the study. OMT, Optimal medical therapy;
TEVAR, thoracic endovascular aorta repair.
Table I. Baseline patient characteristics
TEVAR OMT
No. 208 95
Male, n (%) 154 (74) 65 (68)
Age, mean (SD), years 52.1 (21.8) 55.3 (19.4)
ASA class >III, n (%) 12 (5.8) 4 (4.2)
Hypertension, n (%) 187 (89.9) 61 (64.2)
Renal insufﬁciency, n (%) 16 (7.7) 11 (11.6)
Chronic obstructive pulmonary
disease, n (%)
23 (10.8) 8 (8.4)
Coronary artery disease, n (%) 25 (12) 14 (14.7)
Cerebrovascular accident, n (%) 20 (9.6) 7 (7.4)
Length of LSA entry, mean
(SD), mm
31.3 (22.7) 34.6 (18.8)
Thoracoabdominal extension, n (%) 193 (92.8) 81 (85.3)
ASA, American Society of Anesthesiologists; LSA, left subclavian artery;
OMT, optimal medical therapy; SD, standard deviation; TEVAR, thoracic
endovascular aorta repair.
Table II. Procedural steps in the TEVAR group
Days from onset to operation, median
(range)
23 (16-57)
General anesthesia 194 (93.3)
Duration of procedure, mean (range),
minutes
89 (35-180)
Procedural success 208 (100)
Femoral access 193 (92.8)
Retroperitoneal access 15 (7.2)
Coverage of LSA 76 (36.5)
LSA chimney 9 (4.3)
Surgical bypass 11 (5.3)
LCCA revascularization 11 (5.3)
LCCA, Left common carotid artery; LSA, left subclavian artery; TEVAR,
thoracic endovascular aorta repair.
Values are given as no. (%) unless otherwise indicated.
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coverage of the LSA extending to the proximal landing
zone. Twenty cases required revascularization of the LSA,
including nine by chimney technique and 11 by surgical
bypass. In 5.3% of the cases (11/208), the left common
carotid artery (LCCA) also needed to be covered, and
ancillary carotid carotideleft subclavian bypass surgery
was performed before stent graft placement (Table II).
Early outcome. No deaths occurred during index
hospitalization in the two groups. In the TEVAR group,
early emergency conversion to open surgery was required
in two patients (0.9%) with retrograde type A dissection.
Both survived the complex procedures without adverse
consequences. Six cases (2.9%) experienced brachial artery
pseudoaneurysms due to brachial access, three patients had
spontaneous resolution of their symptoms, and three
needed secondary open repair. Two patients (0.9%) experi-
enced neurologic complications (one paraplegia and one
paraparesis) after TEVAR, but their symptoms resolved
partially during follow-up. Two patients (0.9%) experi-
enced postoperative myocardial infarction without adverse
consequences. Six bare stents (Genesis; Cordis/Johnson
and Johnson, Warren, NJ) were placed in the renal arteries
and four bare stents (Smart; Cordis/Johnson and Johnson)
in the iliac arteries to maintain the branch patency. Iliac
conduits were performed in seven cases after retroperito-
neal access. Proximal type I endoleaks were documented in
25 patients (12%), and proximal cuffs were used in six
patients. In 12 cases (5.8%), LSA coiling was performed to
cure the type II endoleaks. In 28 cases (13.5%), a protec-
tive bare metal stent (Sinus; OptiMed Medical, Ettlingen,
Germany) having a diameter smaller than that of the stent
graft was ﬁrst implanted in the distal landing zone before
the TEVAR procedure. Then the distal end of stent graftwas deployed inside the previous bare stent to avoid
possible overdilation and rupture (Table III). In the OMT
group, no adverse events were recorded within 30 days.
Multivariate logistic regression analysis revealed age >75
years (OR, 3.7; 95% CI, 1.6-12.1; P ¼ .006) and American
Society of Anesthesiologists class greater than III (OR, 2.9;
95% CI, 1.0-7.5; P ¼ .04) as independent predictors of in-
hospital adverse events.
Midterm outcome. The mean follow-up period for
hospital survivors was 28.5 (16.3) months (range, 1.0-58
months). In 68% of patients, more than 24 months of
clinical and imaging follow-up data were available.
In the OMT group, ﬁve patients died from rupture of
an enlarged false lumen, and six patients died suddenly of
unknown reasons, probably due to aorta rupture or
extended dissection. Other causes of deaths were myocar-
dial infarction (n ¼ 1), major stroke (n ¼ 1), and pancreatic
carcinoma (n ¼ 1). Fourteen cases required crossover to
TEVAR (n ¼ 12) or surgical conversion (n ¼ 2) due to
enlargement of the false lumen or acute complications.
One patient died in the ICU of acute myocardial infarction
after the open surgery. Among the 12 TEVAR crossover
patients, four presented with difﬁcult anatomy of the aortic
Table III. Perioperational results after TEVAR
Deaths, n 0
Periprocedural events 12 (5.8)
Retrograde type A dissection 2 (0.9)
Brachial artery pseudoaneurysm 6 (2.9)
Paraplegia/paraparesis 2 (0.9)
Myocardial infarction 2 (0.9)
Auxiliary maneuvers 63 (30.3)
Distal bare metal stent 28 (13.5)
Renal artery stent 6 (2.9)
Iliac stent 4 (1.9)
Iliac conduit 7 (3.4)
Proximal cuff 6 (2.9)
Side branch coiling 12 (5.8)
Hospital stay, mean (range), days 15.4 (4-39)
TEVAR, Thoracic endovascular aorta repair.
Values are given as no. (%) unless otherwise indicated.
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cluding two with LCCAeLSA bypass and two with total
supra-aortic vessel debranching. One patient died of
a major stroke after the total debranching procedure
(Table IV). Thus, the overall mortality in this group
was 16.8% (16/95), and aorta-related mortality was
13.7% (13/95).
In the TEVAR group, nine patients required reinter-
vention or surgical conversion. Indications for reinterven-
tion or conversion were enlargement of the distal false
lumen due to persistent endoleak (n ¼ 3) and rupture of
the distal descending aorta (n ¼ 6). Three patients with
proximal endoleaks were converted to open surgery, and
one died of postoperative multi-organ failure. Six patients
presented with distal aorta rupture and required further
stent graft extension. In four cases, the rupture was found
to be located at the distal landing end of the previous stent
graft. One patient died of delayed retrograde type A dissec-
tion, and four died suddenly of unknown reasons, thought
to be aorta disasters. Other causes of late death included
bronchial carcinoma (n ¼ 2), late-stage gastric carcinoma
(n ¼ 1), rectal carcinoma with metastasis (n ¼ 1), major
stroke (n ¼ 1), acute myocardial infarction (n ¼ 2), and
car accident (n ¼ 1; Table IV). In total, the mortality
rate was 6.7% (14/208), and the aorta-related mortality
rate was 2.9% (6/208).
The cumulative all-cause survival rate (estimated using
Kaplan-Meier curves) in both groups (P ¼ .0678, log-rank
test) is shown in Fig 2, A. Survival probability at 2 and 4
years was 87.5% and 82.7% with TEVAR, respectively,
and 77.5% and 69.1% with OMT, respectively. The
estimated cumulative freedom from aorta-related death
(P ¼ .0392, log-rank test) in the two groups is shown in
Fig 2, B. At 2 and 4 years, survival probability was 91.6%
and 88.1% with TEVAR, respectively, and 82.8% and
73.8% with OMT, respectively. Kaplan-Meier analysis of
a combined end point of aorta-related death, crossover/
conversion for expansion, and ancillary procedures, with
no differences between groups (P ¼ .0978, log-rank test)
is shown in Fig 2, C. At 2 and 4 years, cumulative freedom
from the combined end point was 87.8% and 78.8% withTEVAR, respectively, and 80.9% and 67.8% with OMT,
respectively.
Baseline imaging and follow-up. At the beginning of
the study, all enrolled patients were examined by at least
one tomographic imaging modality, either enhanced CT
or MRI, to obtain a baseline image. Baseline maximum
diameter of the thoracic aorta was 41.2 (19.1) mm (range,
27-52 mm), and the distance from the origin of the LSA to
the proximal entry site was 32.6 (28.9) mm (range, 0-90
mm). Thoracic dissection extended beyond the celiac trunk
in 87.1% of cases (264/303; Table I).
Proximal type I endoleak was documented in 25 of 208
patients (12%) after TEVAR, and spontaneous sealing was
observed in 17 cases during follow-up. Thus, persistent
endoleak was recorded in eight patients in the TEVAR
group, three of whom required surgical conversion for
progressive false-lumen enlargement.
In the TEVAR group, continuous changes of aorta
diameter were recorded in 159 patients, and 49 of the
208 patients (23.5%) were lost to follow-up. Stable (n ¼
39) or decreased (n ¼ 112) size of the thoracic aorta was
observed in 94.9% of patients (151/159; Fig 3), whereas
5.1% (8/159) had an increased size of the thoracic aorta.
Maximum thoracic aorta diameter decreased from 42.4
(23.1) mm to 37.3 (12.8) mm. In the OMT group,
continuous changes of aorta diameter were recorded in
68 cases, and 27 of the 95 patients (28.4%) were lost to
follow-up. Stable (n ¼ 18) or decreased (n ¼ 9) size of
the thoracic aorta were documented in 39.7% of patients
(27/68) and increasing thoracic aorta in 60.3% of patients
(41/68). The incidence of increased thoracic aorta was
signiﬁcantly higher in the OMT group (P ¼ .001). The
maximum thoracic aorta diameter in the OMT group
expanded from 40.7 (18.6) mm to 48.1 (17.3) mm, which
was signiﬁcantly greater than the 37.3 (12.8) mm of the
TEVAR group (P ¼ .002). The remodeling rate of the
thoracic aorta was 88.7% in the TEVAR group and
11.8% in the OMT group. However, the maximum diam-
eter of the abdominal aorta appeared to show no signiﬁcant
difference between the groups (P ¼ .67; Table V).
DISCUSSION
Many institutions acknowledge that TEVAR is an
effective and less invasive treatment of complicated type
B dissection, and close surveillance plus OMT is the stan-
dard treatment modality for chronic uncomplicated
cases.1-4 However, in China TEVAR has often been
considered primary treatment, even for uncomplicated
type B dissection, in the past decade.13-16 The underlying
reasons are complex; possible explanations are that China
has a severe shortage of community doctors, especially in
rural areas, and that China has the world’s largest migrating
population. These factors have made the timely follow-up
of patients more difﬁcult, so the corresponding OMT
results could be impaired.18 Furthermore, no national
consensus or guidelines exist on the treatment of type B
dissection in China, and whether to use TEVAR or
OMT is more often at the discretion of different operators.
Table IV. Midterm outcomes
TEVAR OMT
Overall deaths, n 14 16
Aorta-related deaths 6 (4 unknown reasons) 14 (6 unknown reasons)
Other causes Car accident 1, stroke 1, acute myocardial
infarction 2, cancer 4
Acute myocardial infarction 1, cancer 1, stroke 1
Secondary interventions
Crossover N/A 12
Conversion to surgery 3 2
Extension 6 N/A
OMT, Optimal medical therapy; N/A, not available; TEVAR, thoracic endovascular aorta repair.
Fig 2. A, Kaplan-Meier estimates of overall cumulative survival rate in the two groups (P ¼ .0678 by log-rank test). B,
Kaplan-Meier estimates of aorta-related survival rate in the two groups (P ¼ .0392 by log-rank test). C, Kaplan-Meier
estimates of cumulative freedom from the combined end point of progression and adverse events (P ¼ .0978 by log-
rank test). OMT, Optimal medical therapy; TEVAR, thoracic endovascular aorta repair.
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rate of thoracic aorta have encouraged many Chinese
physicians to prefer TEVAR for treatment of uncompli-
cated type B dissections.Xiong et al13 reported in a systematic review that
patients with type B dissection in China were about 10
years younger than those in the Western world, which sug-
gested potential differences in aorta pathology and
Fig 3. Contrast-enhanced computed tomography (CT) of type B dissection (A) and comparable scans 12 months after
thoracic endovascular aorta repair (TEVAR) (B) showing complete obliteration and progressive resolution of the false
lumen in the thoracic aorta.
Table V. Radiologic follow-up
OMT TEVAR
Maximum diameter of thoracic aorta, mean (SD), mm
Baseline 40.7 (18.6) 42.4 (23.1)
Final 48.1 (17.3) 37.3 (12.8)a
Maximum diameter of abdominal aorta, mean (SD), mm
Baseline 28.5 (17.4) 27.3 (14.7)
Final 31.8 (15.9) 32.7 (12.7)
Stable or decreased size of aorta 39.7% (27/68) 94.9% (151/159)a
Thoracic aorta remodeling 11.8% (8/68) 88.7% (141/159)a
OMT, Optimal medical therapy; SD, standard deviation; TEVAR, thoracic endovascular aorta repair.
aDifference is statistically signiﬁcant.
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data came from retrospective single-center experiences,
and our study is the ﬁrst prospectively designed multicenter
comparative research on the treatment of chronic uncom-
plicated type B dissection in China.14-16Our investigation focused on 303 consecutive patients
with uncomplicated type B aortic dissection enrolled in
four high-volume vascular centers in China. In the TEVAR
group, the technical success rate and perioperative
mortality rate were satisfactory, and serious complications
Fig 4. A, Aorta rupture found at the distal landing zone 15 months after thoracic endovascular aorta repair (TEVAR).
B, TEVAR in another patient with distal protection by an OptiMed bare stent.
Fig 5. Contrast-enhanced computed tomography (CT) of type B dissection (A) and comparable scans 24 months later
(B) and 52 months later with emergent thoracic aorta rupture (C).
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occurred in 1.8% of patients. Although brachial artery pseu-
doaneurysm due to puncture occurred in 2.9% of patients
(6/208), only half of them needed secondary open repair.
Multivariate logistic regression analysis revealed age >75
years and American Society of Anesthesiologists class
greater than III as independent predictors of in-hospital
adverse events. All of these ﬁndings were consistent with
previous observational evidence.3,19-21
For midterm outcome, Kaplan-Meier analysis indicated
seemingly improved 2- and 4-year overall survival rates in
the TEVAR group (87.5% and 82.7%, respectively) vs the
OMT group (77.5% and 69.1%, respectively), although
the differences were not statistically signiﬁcant (P ¼
.0678). However, the freedom from aorta-related mortality
appeared to be signiﬁcantly different between the two
groups, with 2- and 4-year survival rates of 91.6% and
88.1% in TEVAR, respectively, vs 82.8% and 73.8% in
OMT, respectively (P ¼ .0392). These midterm TEVAR
results were comparable with those of the INSTEAD
(Investigation of Stent Grafts in Aortic Dissection) study,
in which overall survival and aorta-related survival rates
were 88.9% and 94.4%, respectively, during a 2-year
period.4 The overall 2-year survival rate and freedom
from aorta-related mortality in our OMT series were
poorer than those in the INSTEAD study (77.5% and
82.8% vs 95.6% and 97%, respectively).4 However, our
OMT results were similar to data reported previously in
the literature.5,6 Estimated freedom from progressive aorta
disease at 24 months was 80.9% and 84.7% in OMT and
TEVAR, respectively, and at 48 months was 67.8% and
78.8%, respectively. Again the difference was not statisti-
cally signiﬁcant (P ¼ .0978), although the results seemed
to favor TEVAR.
During follow-up, six patients in the TEVAR group
presented with descending thoracic aorta rupture, which
in four cases was found to be located near the distal end
of the previous stent graft. This dangerous complication
might have resulted from excessive oversizing of the stent
graft, which was selected according to the diameter of
the proximal aorta and was always much larger than the
narrowed distal aorta. The OptiMed bare stent was used
in later practice before stent graft implantation to avoid
the complication, was selected according to the diameter
of the distal aorta, and was ﬁrst placed in the distal landing
zone before stent graft implantation (Fig 4). This
maneuver was conducted in 28 cases with a narrowed distal
aorta, and none suffered from later rupture.
Radiologic surveillance demonstrated that the thoracic
aorta remained stable or decreased in size in94.9%of patients
in TEVAR groups vs only 39.7% of patients in the OMT
group (P¼ .001). The remodeling rate of the thoracic aorta
was 88.7% in the TEVAR group vs 11.8% in theOMTgroup
(P ¼ .001). A similar increase in the maximum diameter of
the abdominal aorta (about 1 mm/y) was found between
the TEVAR and OMT groups, probably due to the existing
distal reentry sites. These radiologic results are generally
consistent with those reported in the literature.22-25The OMT crossover to TEVAR cases revealed that
continuous expansion of the false lumen could possibly
lead to accelerated kinking of the aortic arch and enlarge-
ment of the primary entry tear, which would make later
TEVAR more challenging and complicated. In our series,
four patients who at ﬁrst were amenable to TEVAR with
relatively benign aortic arch had to undergo a complex
hybrid procedure due to late thoracic aorta expansion
and deteriorative aortic arch (Fig 5).
CONCLUSIONS
This was the ﬁrst prospective multicenter comparative
nonrandomized study on the treatment of type B aortic
dissection in China. In our series, the TEVAR group had
a signiﬁcantly lower aorta-related mortality compared
with the OMT group (P ¼ .0392), but TEVAR failed to
improve the survival rate (P ¼ .0678) or lower the aorta-
related adverse event rate (P ¼ .0978). However, some
major limitations of this study are the nonrandomized,
no-protocol treatment regimen and the large number of
patients lost to follow-up. Further randomized controlled
clinical trials with a larger sample in China are needed
before more deﬁnitive conclusions can be drawn.
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